CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-03 | Ege David S. | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2023-02-03 | von Moltke Lisa | Grant or award · Restricted Stock Units | +47,500 | 47,500 | ||
| 2023-02-03 | von Moltke Lisa | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2023-02-03 | Henn Matthew R. | Grant or award · Restricted Stock Units | +45,000 | 45,000 | ||
| 2023-02-03 | Henn Matthew R. | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-02-03 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Restricted Stock Units | +42,500 | 42,500 | ||
| 2023-02-03 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2023-02-03 | Shaff Eric D. CEO and President | Grant or award · Restricted Stock Units | +125,000 | 125,000 | ||
| 2023-02-03 | Shaff Eric D. CEO and President | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2023-02-03 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units | +42,500 | 42,500 | ||
| 2023-02-03 | Arkowitz David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2023-02-03 | Young Teresa L. | Grant or award · Restricted Stock Units | +42,500 | 42,500 | ||
| 2023-02-03 | Young Teresa L. | Grant or award · Restricted Stock Units | +85,000 | 85,000 | ||
| 2023-02-03 | Young Teresa L. | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2023-02-03 | Cloghessy Paula | Grant or award · Restricted Stock Units | +47,500 | 47,500 | ||
| 2023-02-03 | Cloghessy Paula | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2023-01-04 | Fraser Claire Director | Grant or award · Stock Option (right to buy) | +48,000 | 48,000 | ||
| 2022-10-31 | Ege David S. | Sale | −5,012 | $7.93 | $40K | 46,734 |
| 2022-10-27 | Ege David S. | Grant or award | +20,000 | 51,746 | ||
| 2022-10-27 | Arkowitz David Chief Financial Officer | Grant or award | +42,500 | 112,992 |
Page 19 of 23 · 458 trades